Clinical trial response and dropout rates with olanzapine versus risperidone.
In schizophrenia, comparing treatment dropouts between olanzapine and risperidone can be useful to better understand their relative effectiveness. To analyze the differences in the rates of dropout from clinical trials and response between these 2 antipsychotics. Literature search was based on MEDLINE (1966-May 2002). Analysis 1 included 4 randomized studies (838 patients), analysis 2 included 2 randomized studies (n = 716), and analysis 3 assessed 5 clinical studies for olanzapine (n = 928) and 3 for risperidone (n = 290). Odds ratios were estimated by the fixed-effect model. The risk of treatment discontinuation (analysis 1) was significantly greater for risperidone than for olanzapine (42% vs. 33%, respectively). The response rates were identical for the 2 drugs (analysis 2). A slightly better pattern of maintenance of response was found for olanzapine (analysis 3). The pattern of dropout and maintenance of remission seems to be better controlled for olanzapine than for risperidone.